Tag Archives: cannabidiol

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.

Posted on by
Reply

“Two non-psychoactive cannabinoids, cannabidiol (CBD) and cannabichromene (CBC), are known to modulate in vitro the activity of proteins involved in nociceptive mechanisms, including transient receptor potential (TRP) channels of vanilloid type-1 (TRPV1) and of ankyrin type-1 (TRPA1), the equilibrative nucleoside transporter and proteins facilitating endocannabinoid inactivation. Here we have tested these two cannabinoids on the activity of the descending pathway of antinociception…

CONCLUSIONS AND IMPLICATIONS:

CBD and CBC stimulated descending pathways of antinociception and caused analgesia by interacting with several target proteins involved in nociceptive control.

These compounds might represent useful therapeutic agents with multiple mechanisms of action.”

http://www.ncbi.nlm.nih.gov/pubmed/20942863

Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review.

Posted on by
Reply

“…different cannabis compounds may exert opposite effects on the neuroanatomical changes underlying psychosis. In particular, cannabidiol (CBD) was shown to prevent THC associated hippocampal volume loss… This finding is further supported by several animal experiments supporting neuroprotective properties of CBD mainly via anti-oxidative effects, CB2 receptors or adenosine receptors… mechanisms by which CBD may reduce brain volume loss, including antagonism of THC, interactions with endocannabinoids, and mechanisms that specifically underlie antipsychotic properties of CBD.”

http://www.ncbi.nlm.nih.gov/pubmed/22716143

(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.

Posted on by
Reply

“We have tested a series of (+)-cannabidiol derivatives… for central and peripheral (intestinal, antiinflammatory and peripheral pain) effects in mice…

We conclude that centrally inactive (+)-cannabidiol analogues should be further developed as antidiarrheal, antiinflammatory and analgesic drugs for gastrointestinal and other peripheral conditions.”

http://www.ncbi.nlm.nih.gov/pubmed/15588739

Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.

Posted on by
Reply

“Delta-9 tetrahydrocannabinol (Delta(9)-THC) and (-)-cannabidiol ((-)-CBD) are major constituents of the Cannabis sativa plant with different pharmacological profiles…

We tested a series of (+)- and (-)-CBD derivatives for central and peripheral effects in mice…

We suggest that (+)-CBD analogues have mixed agonist/antagonist activity in the brain.

Second, (-)-CBD analogues which are devoid of cannabinoid receptor affinity but which inhibit intestinal motility, suggest the existence of a non-CB(1), non-CB(2) receptor.

Therefore, such analogues should be further developed as antidiarrheal and/or antiinflammatory drugs.

We propose to study the therapeutic potential of (-)- and (+)-CBD derivatives for complex conditions such as inflammatory bowel disease and cystic fibrosis.”

http://www.ncbi.nlm.nih.gov/pubmed/15910887

Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.

Posted on by
Reply

“Clinical and neurobiological findings suggest that cannabinoids and their receptors are implicated in schizophrenia. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has been reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects…

Our results suggest a potential therapeutical effect of CBD and rimonabant to treat the emotional processing impairment presented in schizophrenia.

In addition, our results reinforce the anxiolytic profile of CBD.”

http://www.ncbi.nlm.nih.gov/pubmed/22716146

Protective Effects of Cannabidiol Against Hippocampal Cell Death and Cognitive Impairment Induced by Bilateral Common Carotid Artery Occlusion in Mice.

Posted on by

“The present study investigated whether cannabidiol (CBD), a major non-psychoactive constituent of marijuana, protects against hippocampal neurodegeneration and cognitive deficits induced by brain ischemia in adult mice…

These findings suggest a protective effect of CBD on neuronal death induced by ischemia and indicate that CBD might exert beneficial therapeutic effects in brain ischemia. The mechanisms that underlie the neuroprotective effects of CBD in BCCAO mice might involve the inhibition of reactive astrogliosis.”

http://www.ncbi.nlm.nih.gov/pubmed/24532152

Physiological intestinal oxygen modulates the Caco-2 cell model and increases sensitivity to the phytocannabinoid cannabidiol.

Posted on by
Reply

“The Caco-2 cell model is widely used as a model of colon cancer… these cells were more sensitive to cannabidiol-induced antiproliferative actions through changes in cellular energetics…

These effects could impact on its development as an anticancer therapeutic…”

http://www.ncbi.nlm.nih.gov/pubmed/24464350

5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.

Posted on by
Reply

“It has been recently reported that cannabidiol (CBD), a non-psychoactive cannabinoid, is able to kill glioma cells, both in vivo and in vitro, independently of cannabinoid receptor stimulation.

…the present investigation indicates that CBD exerts its antitumoral effects through modulation of the LOX pathway and of the endocannabinoid system…”

http://www.ncbi.nlm.nih.gov/pubmed/18028339

Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience.

Posted on by
Reply

“In this article, real-life data from clinical practice showing specific aspects relating to use of 9-delta-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®) in patients with moderate to severe spasticity resistant to usual therapy will be presented…

These case reports highlight the diverse nature of the MS spasticity population and they show the possible usefulness of THC:CBD oromucosal spray in individual patients with moderate to severe spasticity resistant to existing therapies…

Perhaps the most important finding is the possibility of obtaining relevant improvements in QoL/ADL (quality of life/activities of daily living) in some patients with resistant MS spasticity, allowing them to engage back in physical and social activities.”

http://www.ncbi.nlm.nih.gov/pubmed/24457847

THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies.

Posted on by
Reply

“New clinical experience with 9-delta-tetrahydocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex®)…

A randomized, placebo controlled long-term follow-up clinical trial with THC:CBD spray versus placebo demonstrated that it was not associated with cognitive decline, depression or significant mood changes…

THC:CBD oromucosal spray did not adversely influence standard driving ability in patients with moderate to severe MS spasticity…

Findings to date reinforce the efficacy and safety observed in Phase III clinical trials…

Importantly, no additional safety concerns were identified…

Thus, these new data support a positive benefit-risk relationship for THC:CBD oromucosal spray during longer-term use.”

http://www.ncbi.nlm.nih.gov/pubmed/24457846